Disclosed herein are new oral pharmaceutical compositions of SAMDC inhibitors, polyamine analogs, and polyamine biosynthesis inhibitors, and their application for the treatment of conditions including demyelinating diseases, autoimmune disorders affecting the nervous system, and other neurodegenerative conditions. Oral compositions of methylglyoxal bis(guanylhydrazone) (MGBG) combined with fingolimod and a pharmaceutically acceptable carrier are claimed.
